Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis
- PMID: 7492164
- PMCID: PMC1511304
- DOI: 10.1136/adc.73.3.243
Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis
Abstract
The serotonin (5HT3) antagonist ondansetron was compared in a randomised study with metoclopramide and dexamethasone for the prevention of chemotherapy induced emesis. Thirty children aged 1-15 years with acute lymphoblastic leukaemia received 'intensification modules' according to the MRC United Kingdom acute lymphoblastic leukaemia regimen UKALL XI. This contains the moderately emetogenic drugs daunorubicin, etoposide, and cytarabine. Fifteen children received an intravenous loading dose of ondansetron followed by intravenous or oral doses 12 hourly for five days. Fifteen children received intravenous metoclopramide every six hours for three days with a loading dose of dexamethasone, repeated every eight hours for three days intravenously or orally. Efficacy was assessed by a diary card documenting the incidence of nausea, retching, or vomiting. In the 24 hour period after starting chemotherapy, ondansetron was more effective, with a complete or major response rate of 93%, compared with 33% using metoclopramide/dexamethasone.
Similar articles
-
Ondansetron: a review of its use as an antiemetic in children.Paediatr Drugs. 2001;3(6):441-79. doi: 10.2165/00128072-200103060-00007. Paediatr Drugs. 2001. PMID: 11437189 Review.
-
[Recent improvements in antiemetic therapy].Tumori. 1997;83(2 Suppl):S3-14. Tumori. 1997. PMID: 9235727 Review. Italian.
-
Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia.Ann Pharmacother. 1995 Jan;29(1):16-21. doi: 10.1177/106002809502900103. Ann Pharmacother. 1995. PMID: 7711340
-
Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. The Italian Group for Antiemetic Research.J Clin Oncol. 1997 Jan;15(1):124-30. doi: 10.1200/JCO.1997.15.1.124. J Clin Oncol. 1997. PMID: 8996133 Clinical Trial.
-
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.J Clin Oncol. 1990 Jun;8(6):1063-9. doi: 10.1200/JCO.1990.8.6.1063. J Clin Oncol. 1990. PMID: 2140854 Clinical Trial.
Cited by
-
Options for the prevention and management of acute chemotherapy-induced nausea and vomiting in children.Paediatr Drugs. 2003;5(9):597-613. doi: 10.2165/00148581-200305090-00003. Paediatr Drugs. 2003. PMID: 12956617 Review.
-
Ondansetron: a review of its use as an antiemetic in children.Paediatr Drugs. 2001;3(6):441-79. doi: 10.2165/00128072-200103060-00007. Paediatr Drugs. 2001. PMID: 11437189 Review.
-
Acute gastroenteritis in children: role of anti-emetic medication for gastroenteritis-related vomiting.Paediatr Drugs. 2007;9(3):175-84. doi: 10.2165/00148581-200709030-00006. Paediatr Drugs. 2007. PMID: 17523698 Review.
-
2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children.Support Care Cancer. 2017 Jan;25(1):323-331. doi: 10.1007/s00520-016-3384-y. Epub 2016 Aug 26. Support Care Cancer. 2017. PMID: 27565788
-
An overview of the clinical use of ondansetron in preschool age children.Ther Clin Risk Manag. 2007 Jun;3(2):333-9. doi: 10.2147/tcrm.2007.3.2.333. Ther Clin Risk Manag. 2007. PMID: 18360642 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical